Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

National Cancer Institute Search for Clinical Trials
Pathological mechanisms in progressive multiple sclerosis.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Rituximab in paediatric onset multiple sclerosis: a case series.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
TGN1412: From Discovery to Disaster.
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
European Medicines Agency
Food and Drug Administration drug insert for Campath (alemtuzumab)
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.

Pages